Clinical performance of the Roche Cobas 4800 HPV test for primary cervical cancer screening in a Chinese population
Open Access
- 5 August 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (8) , e0272721
Abstract
High-risk human papillomavirus (HR-HPV) testing has become an increasing important strategy in primary cervical cancer screening in recent years. It warrants the evaluation of molecular-based HPV tests for accuracy and efficacy of screening. The performance of Roche Cobas 4800 HPV test was validated and compared with Digene Hybrid Capture 2 (HC2) high-risk HPV DNA test for primary screening in a large Chinese screening cohort. Of 6345 women screened, overall agreement between Cobas and HC2 was 92.23% (95% CI: 91.57–92.89). The inter-assay agreement was correlated with the severity of underlying biology, with an increasing concordance found in samples with more severe abnormalities. Most of the discordant samples had the test signal strength closer to the test limits of the detection than concordant samples, reflecting a low viral load and infection of a cluster of low-risk HPV in these samples. The Cobas test demonstrated significantly higher specificity in identifying CIN2+/CIN3+ cases than HC2 test (66.46% vs 43.67% and 65.42% vs 42.86%, p<0.001), with comparable sensitivity in clinical evaluation. Increased specificity of Cobas test would accent women having the highest risk of developing CIN2+, with the potential to reduce unnecessary colposcopy referral in a screening population.Keywords
This publication has 38 references indexed in Scilit:
- Comparing the performance of six human papillomavirus tests in a screening populationBritish Journal of Cancer, 2013
- Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical CancerVaccine, 2012
- Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trialThe Lancet Oncology, 2012
- Clinical Validation of the cobas 4800 HPV Test for Cervical Screening PurposesJournal of Clinical Microbiology, 2011
- Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA studyThe Lancet Oncology, 2011
- Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trialThe Lancet Oncology, 2010
- HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trialThe Lancet Oncology, 2009
- Papillomaviruses in the causation of human cancers — a brief historical accountVirology, 2009
- Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and olderInternational Journal of Cancer, 2008
- Human Papillomavirus and Papanicolaou Tests to Screen for Cervical CancerNew England Journal of Medicine, 2007